Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.

Study Overview

• Status: Completed
• Conditions: Eczema; Atopic Dermatitis
• Intervention / Treatment: Other: SkinTracker Mobile App

Detailed Description

Mobile health technology, including smartphone apps and wearable monitors, has tremendous potential to transform clinical research. Recording of patient outcomes on a smartphone device and camera in the home setting can greatly reduce the number of in person research visits, saving tremendous costs, time, and effort associated with data entry. This also allows for easier recruitment of study subjects, who can be enrolled in geographic locations beyond academic research centers. After FDA approval of a therapy, mobile health technology can help researchers understand how that particular therapy is being used in a real-world setting, including frequency of use, adverse events, and impact of use on disease symptoms and patient quality of life. In this study, the investigators will create a mobile app to help the atopic dermatitis community understand the types of data and quality of data that can be gathered from atopic dermatitis patients longitudinally. A review of existing atopic dermatitis mobile apps on the market reveals they are consumer-oriented and may not be able to fully capture high-quality research data. The investigator proposed app is specifically geared for research, and thus fills an important gap. The research team will develop SkinTracker, a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting.

• Study Type: Observational
• Enrollment (Actual): 11

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94118
      • UCSF Psoriasis and Skin Treatment Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

This is a single-center, observational, pilot study. Ten subjects with atopic dermatitis will be enrolled.

Description

Inclusion Criteria:

1. Ability to provide written informed consent and comply with the protocol.
2. At least 13 years of age.
3. Diagnosis of atopic dermatitis by dermatologist for at least 6 months.
4. Physical exam within clinically acceptable limits.
5. Own or have access to a mobile device that is compatible with study mobile application SkinTracker.

Exclusion Criteria:

1. Subject is unable to provide written informed consent or comply with the protocol.
2. Unable to input data into SkinTracker mobile app.
3. Subject is younger than 13 years of age.
4. Serious known infection.
5. History of immunosuppression (including human immunodeficiency virus (HIV)).
6. History of malignancy within 5 years prior to screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
7. Severe concomitant illness.
8. Physical exam not within clinically acceptable limits.
9. Subjects possess other diagnoses that, in the investigator's opinion, preclude him/her from safely participating in this study or interfere

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1 patients; Age 18 and above; Eczema Area and Severity Index (EASI) score ≥ 10; Investigator Global Assessment (IGA) ≥ 3	Other: SkinTracker Mobile App; a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Group 2 patients; Age 18 and above; Eczema Area and Severity Index (EASI) score ≥ 1 but < 10; Investigator Global Assessment (IGA) 1 or 2	Other: SkinTracker Mobile App; a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Group 3 patients; Age 12 to 17; Eczema Area and Severity Index (EASI) score ≥ 10; Investigator Global Assessment (IGA) ≥ 3	Other: SkinTracker Mobile App; a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Group 4 patients; Age 12 to 17; Eczema Area and Severity Index (EASI) score ≥ 1 but < 10; Investigator Global Assessment (IGA) 1 or 2	Other: SkinTracker Mobile App; a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average change in eczema area and severity index EASI score at month 6	Patient eczema area and severity index (EASI) will be measured. It is a tool for measuring the amount and severity of eczema a patient has on his or her body, scale is 0-72, 0 means clear and 72 means severe eczema	Month 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average change in eczema area and severity index EASI score at month 3	Patient eczema area and severity index (EASI) will be measured. It is a tool for measuring the amount and severity of eczema a patient has on his or her body, scale is 0-72, 0 means clear and 72 means severe eczema	Month 3
Average change in Investigator global assessment (IGA) at month 6	Patient Investigator global assessment (IGA) score will be measured from 12 to 18 months, it is a scale to estimate overall severity of eczema but does not take into account BSA specifically, scale is 0 to 4, 0 is clear and 4 is severe	Month 6
Average change in Investigator global assessment (IGA) at month 3	Patient Investigator global assessment (IGA) score will be measured from 12 to 18 months, it is a scale to estimate overall severity of eczema but does not take into account BSA specifically, scale is 0 to 4, 0 is clear and 4 is severe	Month 3

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Investigators: Principal Investigator: Wilson Liao, MD, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): April 25, 2022
• Primary Completion (Actual): May 12, 2023
• Study Completion (Actual): May 12, 2023

Study Registration Dates

• First Submitted: May 21, 2020
• First Submitted That Met QC Criteria: May 21, 2020
• First Posted (Actual): May 27, 2020

Study Record Updates

• Last Update Posted (Estimated): January 25, 2024
• Last Update Submitted That Met QC Criteria: January 23, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Dermatitis; Skin Diseases
• Other Study ID Numbers: 19-28676

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No